Tumor Growth in Overdrive: Detailing an Aggressive Course of Hepatocellular Carcinoma

Overview

Journal Case Reports Hepatol

Publisher Wiley

Specialty Gastroenterology

Date 2024 Jul 8

PMID 38974801

Authors

Simardeep Singh

Thilini Delungahawatta

Marcos Wolff

Christopher J Haas

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma ranks as the third leading cause of cancer-related mortality globally. We present a case of a rapidly progressive hepatocellular carcinoma in an 81-year-old female with metabolic abnormalities. The patient initially presented with non-specific signs and symptoms and was managed for sepsis of suspected urinary source. Unresolving laboratory markers led to repeat abdominal imaging demonstrating new hepatic lesions within six days. Biopsy confirmed moderately differentiated hepatocellular carcinoma. The patient received conservative inpatient treatment with recommendation for nutritional and performance status optimization prior to oncologic therapies, however continued to decline and passed away three months later.

References

Ren H, Wang J, Gao Y, Yang F, Huang W . Metabolic syndrome and liver-related events: a systematic review and meta-analysis. BMC Endocr Disord. 2019; 19(1):40. PMC: 6485158. DOI: 10.1186/s12902-019-0366-3. View

Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V . Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2008; 49(3):851-9. DOI: 10.1002/hep.22734. View

McKillop I, Schrum L . Role of alcohol in liver carcinogenesis. Semin Liver Dis. 2009; 29(2):222-32. DOI: 10.1055/s-0029-1214377. View

Jha R, Zanello P, Nguyen X, Pehlivanova M, Johnson L, Fishbein T . Small hepatocellular carcinoma: MRI findings for predicting tumor growth rates. Acad Radiol. 2014; 21(11):1455-64. DOI: 10.1016/j.acra.2014.06.011. View

Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B . Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2020; 70(2):401-407. PMC: 7657990. DOI: 10.1136/gutjnl-2020-321040. View

Kim J, Kim H, Jun M, Yun S, Shim J, Lee H . Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2017; 62(10):2923-2931. DOI: 10.1007/s10620-017-4708-6. View

Lopez-Canovas J, Del Rio-Moreno M, Garcia-Fernandez H, Jimenez-Vacas J, Moreno-Montilla M, Sanchez-Frias M . Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Cancer Lett. 2020; 496:72-83. DOI: 10.1016/j.canlet.2020.10.010. View

Villa E, Critelli R, Lei B, Marzocchi G, Camma C, Giannelli G . Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2015; 65(5):861-9. DOI: 10.1136/gutjnl-2014-308483. View

Chen J, Zhu J, Wang G, Groopman J, Kensler T . Qidong: a crucible for studies on liver cancer etiology and prevention. Cancer Biol Med. 2019; 16(1):24-37. PMC: 6528445. DOI: 10.20892/j.issn.2095-3941.2018.0394. View

10.

Rich N, John B, Parikh N, Rowe I, Mehta N, Khatri G . Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology. 2020; 72(5):1654-1665. PMC: 7398837. DOI: 10.1002/hep.31159. View

11.

Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R . Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2004; 125(6):1733-41. DOI: 10.1053/j.gastro.2003.09.035. View

12.

Oh J, Won Jun D . The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol. 2023; 29(2):355-357. PMC: 10121295. DOI: 10.3350/cmh.2023.0070. View

13.

Jee H, Park M, Lee H, Park M, Kim M, Chung Y . Is Non-Contrast CT Adequate for the Evaluation of Hepatic Metastasis in Patients Who Cannot Receive Iodinated Contrast Media?. PLoS One. 2015; 10(7):e0134133. PMC: 4517761. DOI: 10.1371/journal.pone.0134133. View

14.

Jinjuvadia R, Patel S, Liangpunsakul S . The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol. 2014; 48(2):172-7. PMC: 3887366. DOI: 10.1097/MCG.0b013e3182a030c4. View

15.

Tumen D, Heumann P, Gulow K, Demirci C, Cosma L, Muller M . Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines. 2022; 10(12). PMC: 9775527. DOI: 10.3390/biomedicines10123202. View

16.

Cowey S, Hardy R . The metabolic syndrome: A high-risk state for cancer?. Am J Pathol. 2006; 169(5):1505-22. PMC: 1780220. DOI: 10.2353/ajpath.2006.051090. View

17.

El-Serag H, Hampel H, Javadi F . The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4(3):369-80. DOI: 10.1016/j.cgh.2005.12.007. View

18.

Lopez-Canovas J, Herman-Sanchez N, Del Rio-Moreno M, Fuentes-Fayos A, Lara-Lopez A, Sanchez-Frias M . PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing. Exp Mol Med. 2023; 55(1):132-142. PMC: 9898568. DOI: 10.1038/s12276-022-00917-7. View

19.

Calderon-Martinez E, Landazuri-Navas S, Vilchez E, Cantu-Hernandez R, Mosquera-Moscoso J, Encalada S . Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. J Clin Med Res. 2023; 15(4):200-207. PMC: 10181349. DOI: 10.14740/jocmr4902. View

20.

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View